Business
Synbio International Inc. Strengthens Strategic Alliance with FacialDx Inc. through Share Purchase and Warrant Agreements
The Share Purchase Agreement (SPA) secures an equity stake in FacialDx and secures ownership in its intellectual property by way of the shareholding.The SPA also enables Synbio to convert future clinical trial expenditures into additional equity in FacialDx at today’s valuation, unlocking substantial upside potential as FaciaDx also scales commercially.A Joint Trial Committee will be established to oversee the design, conduct, and reporting of all clinical studies, maximizing the likelihood of F
About this update from Synbio International Inc.
[{"type":"image","alt":"Synbio International Inc.","displaySize":"","headline":null,"caption":"Synbio International Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":247,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/c71b2af44e5cfefae1b6359e245301fc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2LrUyAfS_sQOct8RmO9mSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c71b2af44e5cfefae1b6359e245301fc","width":247,"height":58}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The Share Purchase Agreement (SPA) secures an equity stake in FacialDx and secures ownership in its intellectual property by way of the shareholding.","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"The SPA also enables Synbio to convert future clinical trial expenditures into additional equity in FacialDx at today’s valuation, unlocking substantial upside potential as FaciaDx also scales commercially.","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"A Joint Trial Committee will be established to oversee the design, conduct, and reporting of all clinical studies, maximizing the likelihood of FDA approval and successful commercialization.","length":190,"tagName":"p"}]},{"val":[{"type":"text","content":"The agreements align FacialDx’s commercial momentum with Synbio’s clinical and regulatory expertise, paving a clear path towards FDA submission and market adoption.","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Through the Warrant Agreement, FacialDx has the right to acquire Synbio’s common stock upon FDA approval, securing reciprocal value and fostering long-term partnership alignment.","length":178,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":887,"olType":false},{"type":"text","content":"NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Synbio International Inc. (OTC: SYIN) (“Synbio” or the “Company”) is pleased to announce the execution of a Share Purchase Agreement and Warrant Agreement (SPA) with FacialDx, Inc., further strengthening the strategic partnership established under the Clinical Trial License Agreement (CTLA) signed earlier this year.","length":361,"tagName":"p"},{"type":"text","content":"These agreements strengthen Synbio’s partnership with FacialDx and extend the benefits to Synbio shareholde...